SEC Form 4 · accession 0001179110-18-012637
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Albers
Officer — CEO and President · Director
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 5, 2018 | M | 20,000 | $1.87 | A | 20,000 | D | |
| Common StockF3 | Nov 5, 2018 | S | 1,100 | $65.53 | D | 18,900 | D | |
| Common StockF4 | Nov 5, 2018 | S | 1,500 | $64.18 | D | 17,400 | D | |
| Common StockF5 | Nov 5, 2018 | S | 17,300 | $63.30 | D | 100 | D | |
| Common StockF6 | Nov 5, 2018 | S | 100 | $62.66 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $1.87 | Nov 5, 2018 | M | 20,000 | D | — | Jul 30, 2024 | Common Stock | 20,000 | 915,034 | D |
Explanation of responses
- F1The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.84 to $64.81 per share.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.77 to $63.76 per share.
- F6The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.65 to $62.66 per share.
- F7This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018.